THE Pharmaceutical Society
of Australia says its upcoming
PAC13 conference, in Brisbane
10-13 Oct, will give delegates an
unprecedented opportunity to
broaden their skills and learn from
researchers, practitioners and
consumers about developments
that will help shape the future of
our profession and its part in the
changing health-care environment.
The PAC13 program will present
more than 56 hours of CPD - 11.5
Group 1 and 90 Group 2 credits -
from which delegates will be able
to select topics of their choice.
There is a major focus on Group
2 credits, with attendees able to
achieve 25.5 CPD credits including
21 group 2 credits, while attending
the conference.
Full program information, CPD
allocation and online registration
are at www.psa.org.au/pac.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Sep 13
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.